全文获取类型
收费全文 | 102883篇 |
免费 | 5054篇 |
国内免费 | 163篇 |
专业分类
耳鼻咽喉 | 1238篇 |
儿科学 | 3767篇 |
妇产科学 | 5496篇 |
基础医学 | 12262篇 |
口腔科学 | 3134篇 |
临床医学 | 9356篇 |
内科学 | 22088篇 |
皮肤病学 | 2433篇 |
神经病学 | 11361篇 |
特种医学 | 4087篇 |
外科学 | 14805篇 |
综合类 | 435篇 |
一般理论 | 65篇 |
预防医学 | 5333篇 |
眼科学 | 2259篇 |
药学 | 4259篇 |
中国医学 | 106篇 |
肿瘤学 | 5616篇 |
出版年
2023年 | 2095篇 |
2022年 | 2475篇 |
2021年 | 3281篇 |
2020年 | 3346篇 |
2019年 | 2496篇 |
2018年 | 2664篇 |
2017年 | 2510篇 |
2016年 | 2585篇 |
2015年 | 2131篇 |
2014年 | 4509篇 |
2013年 | 4069篇 |
2012年 | 4133篇 |
2011年 | 4031篇 |
2010年 | 3607篇 |
2009年 | 3419篇 |
2008年 | 3908篇 |
2007年 | 4554篇 |
2006年 | 4433篇 |
2005年 | 4084篇 |
2004年 | 4130篇 |
2003年 | 3914篇 |
2002年 | 3628篇 |
2001年 | 3554篇 |
2000年 | 3539篇 |
1999年 | 3199篇 |
1998年 | 1093篇 |
1997年 | 854篇 |
1996年 | 698篇 |
1995年 | 721篇 |
1994年 | 622篇 |
1993年 | 634篇 |
1992年 | 2212篇 |
1991年 | 2049篇 |
1990年 | 1930篇 |
1989年 | 1869篇 |
1988年 | 1785篇 |
1987年 | 944篇 |
1986年 | 377篇 |
1985年 | 601篇 |
1984年 | 698篇 |
1983年 | 424篇 |
1982年 | 530篇 |
1981年 | 471篇 |
1980年 | 412篇 |
1979年 | 366篇 |
1978年 | 336篇 |
1977年 | 317篇 |
1976年 | 250篇 |
1975年 | 191篇 |
1974年 | 229篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
102.
103.
104.
《Clinical genitourinary cancer》2022,20(6):594-602
The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to systematically identify and review published economic evaluations (EEs) related to the treatment of mHSPC and assess their quality. A systematic search was performed of the PubMed and Cochrane databases. Three reviewers independently selected EEs by defined inclusion and exclusion criteria. They extracted all data from each EE (general information, study population, data about the EE, interventions and comparators, and outcomes). They also assessed the quality of the selected EEs according to Drummond's checklist. Fourteen EEs published between 2016 and 2021 were eligible for the systematic review. The EEs found ADT + docetaxel to be the most cost-effective of all available treatments as a first-line strategy for mHSPC (abiraterone acetate plus prednisone, enzalutamide, and apalutamide). Five EEs showed that a simple price reduction of abiraterone acetate of 50% to 75% could change the results to render this treatment also cost-effective relative to that with docetaxel. Twelve EEs were of high quality, with a Drummond score ≥ 7. Analysis of the 14 EEs identified by our systematic review, amongst which 78.6% met high quality standards, showed that ADT + docetaxel tends to be the most cost-effective alternative for mHSPC. These results were assessed by sensitivity analysis. The data provided by this systematic review help to provide a better understanding of these treatments and the better use of healthcare resources. 相似文献
105.
106.
107.
108.
109.
110.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):460-468.e2
ObjectivesDonor-specific cell-free DNA shows promise as a noninvasive marker for allograft rejection, but as yet has not been validated in both adult and pediatric recipients. The study objective was to validate donor fraction cell-free DNA as a noninvasive test to assess for risk of acute cellular rejection and antibody-mediated rejection after heart transplantation in pediatric and adult recipients.MethodsPediatric and adult heart transplant recipients were enrolled from 7 participating sites and followed for 12 months or more with plasma samples collected immediately before all endomyocardial biopsies. Donor fraction cell-free DNA was extracted, and quantitative genotyping was performed. Blinded donor fraction cell-free DNA and clinical data were analyzed and compared with a previously determined threshold of 0.14%. Sensitivity, specificity, negative predictive value, positive predictive value, and receiver operating characteristic curves were calculated.ResultsA total of 987 samples from 144 subjects were collected. After applying predefined clinical and technical exclusions, 745 samples from 130 subjects produced 54 rejection samples associated with the composite outcome of acute cellular rejection grade 2R or greater and pathologic antibody-mediated rejection 2 or greater and 323 healthy samples. For all participants, donor fraction cell-free DNA at a threshold of 0.14% had a sensitivity of 67%, a specificity of 79%, a positive predictive value of 34%, and a negative predictive value of 94% with an area under the curve of 0.78 for detecting rejection. When analyzed independently, these results held true for both pediatric and adult cohorts at the same threshold of 0.14% (negative predictive value 92% and 95%, respectively).ConclusionsDonor fraction cell-free DNA at a threshold of 0.14% can be used to assess for risk of rejection after heart transplantation in both pediatric and adult patients with excellent negative predictive value. 相似文献